Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/342154

Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth

Description:

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Current research is focusing on the urgent unmet need for agents that improve survival. Improved responses from treatment regimens that combine targeted biological agents with established chemotherapy, as well as increased drug therapy for early-stage patients who are likely to progress based on potential prognostic markers, have already begun and will continue to create market opportunities and propel steady growth of the CLL market.

In this report, we provide an overview of CLL, including its staging, epidemiology, and biological markers. We discuss the current treatments and promising late-stage agents in development for CLL, as well as the market outlook though 2010.

Business Implications

- Chronic lymphocytic leukemia is the most common leukemia in the Western world, with more than 160,000 people affected in the seven major markets we cover. Although the American Cancer Society (ACS) estimates that the U.S. incidence of CLL has decreased by 1.9% per year since 1992, there were still an estimated 9,100 new cases of CLL in the United States in 2005; the ACS also estimates that CLL caused 4,600 deaths in 2005. While CLL is considered incurable, recent advances in combination chemoimmunotherapy (monoclonal antibodies [MAbs] in combination with chemotherapy) have produced the best responses to date in all lines of CLL treatment.

- Currently, the only MAb approved for use in CLL patients is alemtuzumab (Schering AG’s MabCampath, Berlex’s Campath), which has achieved significant success when used in combination with fludarabine (Schering AG/Berlex’s Fludara, generics) in refractory patients. Off-label use of rituximab (Biogen Idec/Genentech’s Rituxan), currently in Phase III for CLL, has had significant success in combination with fludarabine and cyclophosphamide (Bristol-Myers Squibb’s Cytoxan, Baxter’s Endoxan/Endoxana, Pfizer’s Neosar/Cyclostin, generics) in previously untreated patients, and we expect its adoption to increase when rituximab is approved.

- Currently, the greatest unmet need in the CLL market is for an agent that will prolong survival. Several new agents in development seek to achieve this goal, including immune system modulators (such as MAbs and immunotoxins), cell-cycle inhibitors, proteasome inhibitors, apoptosis inducers, and angiogenesis inhibitors. Stem cell transplantation (SCT) offers the only chance for a cure for CLL. Although mortality and morbidity rates with this developmental procedure are high, new nonmyeloablative procedures have significantly improved its safety, and we expect its use to increase.

- In 2005, the CLL market in the United States was approximately $153 million, with MAbs making up 77% of the market. We expect the market to continue to grow steadily over the next five years, driven by the continued dominance of MAbs, the approval of rituximab, and the identification of prognostic markers for patients at risk of progression, which will result in increased drug therapy in early-stage patients.

Contents:

Introduction
Overview of Chronic Lymphocytic Leukemia
Disease Characteristics
Etiology and Pathophysiology
Symptoms
Staging and Survival
Epidemiology
Role of Biological Markers in Prognosis
Current Treatment Options for Chronic Lymphocytic Leukemia
Treatment Decisions
First-Line Therapies
Second-Line Therapies
Third-Line Therapies
Emerging Therapies for Chronic Lymphocytic Leukemia
Monoclonal Antibodies
Rituximab
Lumiliximab
Other Monoclonal Antibodies
Immunotoxins
Cell-Cycle Inhibitors
Antisense Oligonucleotides
Market Outlook

Table 1 Common Staging Systems Used in the Treatment of CLL
Table 2 Select Current Therapies Used for the Treatment of CLL, 2006
Table 3 NCI Definition of Response to Treatment in CLL Patients
Table 4 Select Emerging Therapies for the Treatment of CLL in the United States, 2006

Figure 1 Treatment Algorithm for Chronic Lymphocytic Leukemia

Companies Mentioned

- Schering AG - Berlex - Biogen Idec - Genentech - Bristol-Myers Squibb - Baxter - Pfizer - GlaxoSmithKline - SuperGen - Wyeth - Ortho-Biotech - Eli Lilly - Genzyme - Chiron - Genmab - Ligand - Genta - Pharmacyclics - Cephalon - Millennium Pharmaceuticals - Bioenvision - Celgene - Point Therapeutics - BioCryst Pharmaceuticals

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/342154

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 05/09/2008 21:50:57

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com

Order information

Please verify that the product information is correct and select the format you require.


Product Name:
Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth
Web Address:
http://www.researchandmarkets.com/reports/342154
Office Code:
OCHHGMMRVRY

Report formats

Please enter the quantity of the report format you require.

	Format	Quantity	Price
	Electronic (PDF) - Single User		€1,043.00

Contact information

Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Page 2 of 2
Printed 05/09/2008 21:50:57

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder Name:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World